Marsh & McLennan Companies, Inc. (MRSH)

FairStock Score: 57/100 — STEADY

Key Financials

Strengths

• Exceptional ROE of 29.35% demonstrates superior capital efficiency and competitive moat strength
• Robust free cash flow generation of $4.7 billion provides financial flexibility and dividend capacity
• Diversified global platform across risk management and consulting with recurring revenue characteristics
• Low systematic risk (beta 0.73) provides defensive characteristics during market downturns
• Strong net margins of 12.45% in latest quarter indicate pricing power and operational efficiency

Concerns

• Valuation disconnect: trading at $179.97 versus Graham Number of $34.41 represents extreme overvaluation with -423% margin of safety
• Weak ROCE of 7.51% suggests returns on incremental capital investments fall short of cost of capital
• Elevated leverage at 1.40 D/E ratio combined with high valuation multiples limits downside protection
• EV/EBITDA of 70.40 implies unrealistic growth expectations that mature financial services firms rarely achieve
• Missing growth metrics and EPS data obscure near-term revenue trajectory and earnings quality

AI Analysis

Marsh & McLennan presents an interesting paradox—a genuinely high-quality business trading at a price that demands careful scrutiny. The company boasts exceptional returns on equity at 29.35% and generates substantial free cash flow of $4.7 billion annually, suggesting a durable competitive moat in insurance brokerage and consulting. Their 95,000-employee platform provides sticky, recurring revenue streams across risk management and consulting segments, with Q4 2025 showing respectable 12.45% net margins. However, I must confront the valuation reality: at $179.97 per share against Graham's calculated intrinsic value of $34.41, we face a 423% margin of negative safety. The P/E of 20.91, combined with an EV/EBITDA of 70.40, suggests the market has priced in perpetual growth at rates rarely achieved in mature financial services. While the 0.73 beta indicates stability and the Piotroski F-Score of 7/9 shows decent operational health, the 7.51% ROCE troubles me—far below the cost of capital these metrics imply. The leverage ratio of 1.40 is manageable but warrants monitoring. This is a compounder's business quality at a speculator's price. Unless revenue growth accelerates substantially beyond historical norms, current shareholders face modest returns ahead. I would watch this company, but only at a significant discount.

Bull Case

Marsh & McLennan's market-leading position in insurance brokerage and growing consulting revenues could drive consistent mid-to-high single-digit growth indefinitely, justifying premium valuations if the company captures structural tailwinds from increasing regulatory complexity and risk management demand. Strong capital returns and margin expansion could deliver 8-10% annual returns for patient shareholders betting on business quality compounding.

Bear Case

If the insurance brokerage market faces pricing pressure or consulting demand softens, the company's modest ROCE of 7.51% will fail to support current valuation multiples, potentially triggering significant multiple compression. A 30-40% correction from current levels would be justified if growth disappoints or competitive intensity increases.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer